The vaccine against dengue developed by the Butantan Institute is already at the end of phase 3 of tests, which is the application and monitoring of the effectiveness of the immunizing agent in approximately 17 thousand volunteers. This phase of the study is expected to be completed in 2024, with the release of its results. Then, with the approval of Anvisa – the National Health Surveillance Agency – the immunizing agent can be made available to the general population.
The vaccine developed uses the weakened virus technique, which induces the production of antibodies without causing the disease; it will be tetravalent, protecting against the four types of dengue; and will be applied in just one dose.
The attenuation of the virus was carried out by the National Institute of Allergies and Infectious Diseases of the United States, one of Butantan’s partners in the development of the vaccine.
Alexander Precioso, director of Pharmacovigilance at Butantan, spoke of the importance of having a vaccine against dengue, since the disease is already considered a global health problem by the WHO.
In addition to the vaccine, the researchers point out that it is important to maintain measures to prevent the spread of the mosquito, such as avoiding leaving standing water in outdoor environments, the main breeding grounds for the Aedes Aegypti mosquito.
According to the latest bulletin of arboviruses from the Ministry of Health, this year the country has registered more than 491,000 cases of dengue, with 209 deaths. The WHO estimates that 390 million people in the world are infected by the disease each year.